⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 22, 2024Digestive and Liver DiseaseOpen Access

Differences in clinical manifestations and the fecal microbiome between irritable bowel syndrome and small intestinal bacterial overgrowth

Siqi Lu Yuzhu Chen Huaizhu Guo Zuojing Liu Yanlin Du Liping Duan

View Full Paper

Ask AI

Bookmark

Share

Abstract

Irritable bowel syndrome (IBS) and small intestinal bacterial overgrowth (SIBO) share similar abdominal symptoms; however, their differentiation remains controversial.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lu et al. (2024) studied this question.

synapsesocial.com/papers/68e5f733b6db64358758ba16 https://doi.org/10.1016/j.dld.2024.07.011

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1IBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological InterventionsReview · 2026 · 4 citations
2Small intestinal bacterial overgrowth syndrome (SIBO) - clinical manifestations, diagnosis and therapeutic options2024
3THE ROLE OF SMALL INTESTINAL BACTERIAL OVERGROWTH IN THE PATHOGENESIS, MANAGEMENT AND QUALITY OF LIFE IN PATIENTS WITH IRRITABLE BOWEL SYNDROME – A LITERATURE REVIEWSystematic Review · 2026
4Modern concepts of small intestinal bacterial overgrowth2025 · 10 citations
5Small Intestinal Bacterial Overgrowth2024 · 10 citations

More related papers

Targeted antibiotic and dietary approaches in managing small intestinal bacterial overgrowth across irritable bowel syndrome subtypes2026
Prevalence, clinical significance and predictors of small intestinal bacterial overgrowth and elevated fecal calprotectin in refractory irritable bowel syndrome: Insights from a prospective cross-sectional study.2026
Small Intestinal Bacterial Overgrowth (SIBO) and Twelve Groups of Diseases Related- Current State of Knowledge2024

More from Digestive and Liver Disease

Cardiac remodelling in a mouse model of progressive metabolic dysfunction-associated steatotic liver diseaseTue,
Internal and Temporal Risk Discrimination in MASLD-Related Cirrhosis Presenting to Emergency CareTue,